Skip to main content
Premium Trial:

Request an Annual Quote

Accelr8 Shares Up 8 Percent on Patent News

NEW YORK, Feb. 3 (GenomeWeb News) - Shares in Accelr8 were up 7.95 percent, or $.21, at $2.85 in late-afternoon trading after the company said it won a US patent for its OptiChem surface chemistry.


The stock shot up to $3.35 in early-morning trade before settling down to $2.85 in unusually heavy volume.


The patent, No. 6,844,028, covers a new coating that "makes it possible to selectively capture, target and analyze individual bacteria. ... "


OptiChem is a component of Accelr8 's new BACcelr8r diagnostic system that, "when fully developed, has the potential to replace bacterial culturing by producing test results in a matter of hours," the company said. Results from traditional culturing "typically require several days," Accelr8 said.

Accelr8 currently sells OptiChem-coated slides for research applications, and is developing custom coating formulations for industrial clients.

The Scan

Mosquitos Genetically Modified to Prevent Malaria Spread

A gene drive approach could be used to render mosquitos unable to spread malaria, researchers report in Science Advances.

Gut Microbiomes Allow Bears to Grow to Similar Sizes Despite Differing Diets

Researchers in Scientific Reports find that the makeup of brown bears' gut microbiomes allows them to reach similar sizes even when feasting on different foods.

Finding Safe Harbor in the Human Genome

In Genome Biology, researchers present a new approach to identify genomic safe harbors where transgenes can be expressed without affecting host cell function.

New Data Point to Nuanced Relationship Between Major Depression, Bipolar Disorder

Lund University researchers in JAMA Psychiatry uncover overlapping genetic liabilities for major depression and bipolar disorder.